B-Cell Malignancies: Why Not All BTK Inhibitors Are Created Equal

Join our expert faculty as they discuss next-generation BTK inhibitors, with a focus on specificity, efficacy, and tolerability. Credit available for this activity expires: 11/16/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/962783?src=mkm_podcast_addon_962783